Novel Fluorescent Compound for Treating Prostate Cancer by Restoring RASSF1A Expression

OVERVIEW

This invention presents a novel approach to prostate cancer treatment, addressing the challenge of androgen-independent tumors through the administration of a dansyl-carbazole compound. Offering methods for cancer treatment, cell growth suppression, and cancer cell identification, this invention promises a significant advancement in combating prostate cancer and potentially other cancers with decreased RASSF1A expression.

BACKGROUND

In cancer treatment, the epigenetic silencing of the RASSF1A protein poses significant challenges, leading to disrupted cell cycle control and apoptotic resistance. Regarding prostate cancer, conventional hormone ablation therapies have shown limitations, particularly in addressing androgen-independent tumors. Ectopic expression of RASSF1A can reverse this tumorigenic phenotype, indicating a potential avenue for therapeutic intervention. The newly discovered fluorescent carbazole compound showcased in this invention not only up-regulates RASSF1A but also demonstrates heightened potency and intracellular localization, marking a crucial breakthrough in prostate cancer therapy.

Benefit

• Targeted therapy for androgen-independent prostate cancer, overcoming limitations of conventional hormone ablation methods.
• Potential for tumor regression and suppression of cancer cell growth, offering improved outcomes for patients with advanced-stage prostate cancer.
• Versatile applications in cancer treatment, providing a new avenue for addressing cancers with decreased RASSF1A expression.

Market Application

• Oncology: Offers a new solution to prostate cancer treatment by targeting androgen-independent tumors, with potential applications in other cancers exhibiting decreased RASSF1A expression.
• Pharmaceutical Industry: Presents opportunities for the development of innovative cancer therapies and personalized medicine approaches targeting specific molecular pathways.
• Biomedical Research: Provides a valuable tool for studying epigenetic mechanisms and developing targeted cancer therapies.

Publications

US Patent No. 10, 457, 639

Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft. J Med Chem. 2010 Mar 25;53(6):2376-82. doi: 10.1021/jm9011615.